Alzheimer's Disease - Input of Vitamin D With mEmantine Assay (AD-IDEA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01409694 |
|
Recruitment Status :
Completed
First Posted : August 4, 2011
Last Update Posted : September 22, 2016
|
Sponsor:
University Hospital, Angers
Information provided by (Responsible Party):
University Hospital, Angers
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to compare the effect after 24 weeks of the oral intake of vitamin D3 (cholecalciferol) with the effect of a placebo on the change of cognitive performance in patients suffering from moderate Alzheimer's disease or related disorders (ADRD) and receiving memantine.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Alzheimer Disease | Drug: Memantine Drug: Vitamin D Drug: Vitamin D placebo | Phase 3 |
Current treatments for Alzheimer's disease and related disorders (ADRD) are symptomatic and can only temporarily slow down ADRD. Future possibilities of care could rely on multi-target drugs therapies that address simultaneously several pathophysiological processes leading to neurodegeneration. We hypothesized that the combination of memantine with vitamin D could be neuroprotective in ADRD, thereby limiting neuronal loss and cognitive decline.
The primary objective of this trial is to compare the effect after 24 weeks of the oral intake of vitamin D3 with the effect of a placebo on the evolution of cognitive performance in patients suffering from moderate ADRD and receiving memantine.
The secondary objectives of the study are as follows:
- To compare the effect after 12 weeks of the oral intake of vitamin D3 with the effect of a placebo on the evolution of cognitive performance in patients suffering from moderate ADRD and receiving memantine.
- To compare the effect after 12 and 24 weeks of the oral intake of vitamin D3 with the effect of a placebo on the evolution of functional abilities in patients suffering from moderate ADRD and receiving memantine.
- To compare the effect after 12 and 24 weeks of the oral intake of vitamin D3 with the effect of a placebo on the evolution of postural and gait performance in patients suffering from moderate ADRD and receiving memantine.
- To determine the compliance to treatment and tolerance of the oral intake of vitamin D3 in patients suffering from moderate ADRD and receiving memantine.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 90 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Evaluation d'Une stratégie thérapeutique d'Association médicamenteuse Pour la Prise en Charge de la Maladie d'Alzheimer et Des Maladies apparentées au Stade modéré |
| Study Start Date : | September 2011 |
| Actual Primary Completion Date : | January 2016 |
| Actual Study Completion Date : | January 2016 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Alzheimer disease
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Intervention
All participants start the treatment with memantine on the first day of the study and immediately start vitamin D supplementation.
|
Drug: Memantine
Memantine is administered to all participants according to the usual strategy, with upward titration of 5 mg per week during the first three weeks to reduce the risk of side effects. The final dosage is 20 mg per day, with no subsequent modification of dosage or specialty during the trial.
Other Name: Chlorhydrate de mémantine (Ebixa®) Drug: Vitamin D Subjects receive Vitamin D supplementation (cholecalciferol 100,000 IU, drinking solution, 2 mL vial) at a rate of 1 drinking vial of 100,000 IU cholecalciferol every month. In brief, the total dose is 600,000 IU over the duration of the study starting with one vial at the time of inclusion, then at week(W) 4, W8, W12, W16 and W20. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study.
Other Name: Colecalciferol |
|
Placebo Comparator: Placebo
Participants in this arm start the treatment with memantine in the same way as the 'Intervention' group. They also immediately start Vitamin D placebo administered at the same pace.
|
Drug: Memantine
Memantine is administered to all participants according to the usual strategy, with upward titration of 5 mg per week during the first three weeks to reduce the risk of side effects. The final dosage is 20 mg per day, with no subsequent modification of dosage or specialty during the trial.
Other Name: Chlorhydrate de mémantine (Ebixa®) Drug: Vitamin D placebo Subjects receive Vitamin D placebo (drinking solution, 2mL vial) at a rate of 1 drinking vial every month. In brief, the subjects start with one vial at the time of inclusion, then at week(W)4, W8, W12, W16 and W20. The placebo drinking solution contains all the excipients present in the Vitamin D vial.
Other Name: Placebo |
Primary Outcome Measures :
- Change in cognitive performance [ Time Frame: This outcome is assessed at baseline, 12 and 24 weeks after inclusion ]Cognitive performance is measured with Alzheimer's Disease Assessment Scale-cognition score (ADAS-cog)
Secondary Outcome Measures :
- Change in other cognitive scores [ Time Frame: This outcome is assessed at baseline, 12 and 24 weeks after inclusion ]MMSE, Cognitive Assessment Battery, Frontal Assessment Battery, Trail Making Test parts A and B
- Change in functional performance [ Time Frame: This outcome is assessed at baseline, 12 and 24 weeks after inclusion ]Activities of Daily Living scale and 4-item Instrumental Activities of Daily Living scale
- Change in posture and gait [ Time Frame: This outcome is assessed at baseline, 12 and 24 weeks after inclusion ]Timed Up & Go, Five Time Sit-to-Stand and spatio-temporal analysis of walking
- Between-group comparison of compliance to treatment and tolerance [ Time Frame: This outcome is assessed at baseline, 12 and 24 weeks after inclusion ]These outcomes are assessed together with the serum concentrations of 25OHD, calcium and parathyroid hormone.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 60 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age ≥ 60 years
- Diagnosis of moderate Alzheimer's disease or related disorders (DSM-IV/NINCDSADRDA) with a score of Mini-Mental State Examination (MMSE) between 10 and 20 inclusively
- To have hypovitaminosis D (i.e., serum 25-hydroxyvitamin D [25OHD]concentration < 30 ng/mL)
- To have no hypercalcemia (defined as serum calcium concentration ≥ 2,65 mmol/L)
- To have given and signed an informed consent form to participate in the trial (or informed consent form obtained from the trusted person or legal representative, as appropriate)
- To be affiliated to French Social Security
Exclusion Criteria:
- The use of standard antidementia drugs (i.e., anticholinesterasics, memantine, or vasodilatators) in the past 60 days
- Severe hepatic or renal failure
- Severe, unstable or poorly controlled medical conditions at the time of the inclusion
- Other cognitive disorders (untreated dysthyroid, deficiency in vitamin B9 or B12, chronic ongoing ethylism, history of syphilis, stroke, delirium revealed with the Confusion Assessment Method (CAM), severe depressive symptomatology (Geriatric Depression score ≥ 10/15))
- Contra-indications to memantine or vitamin D
- Enrollment in another simultaneous clinical trial
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01409694
Locations
| France | |
| University Hospital | |
| Angers, France, 49933 | |
Sponsors and Collaborators
University Hospital, Angers
Investigators
| Principal Investigator: | Cédric Annweiler, MD, PhD | Angers University Hospital |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | University Hospital, Angers |
| ClinicalTrials.gov Identifier: | NCT01409694 History of Changes |
| Other Study ID Numbers: |
2010-024506-35 |
| First Posted: | August 4, 2011 Key Record Dates |
| Last Update Posted: | September 22, 2016 |
| Last Verified: | March 2011 |
Keywords provided by University Hospital, Angers:
|
Alzheimer Disease Vitamin D Cholecalciferol Memantine Cognition Disorders |
Additional relevant MeSH terms:
|
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders Vitamins Vitamin D Ergocalciferols Cholecalciferol |
Memantine Micronutrients Growth Substances Physiological Effects of Drugs Bone Density Conservation Agents Antiparkinson Agents Anti-Dyskinesia Agents Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents |